"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...

Assessing patient fitness involves more than evaluating chronological age, noted Brandon Blue, MD, of the Moffitt Cancer ...

A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

Patients with relapsed/refractory multiple myeloma could benefit from repeat treatment with drugs their disease has ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...